Distribuzione geografica
Continente #
NA - Nord America 6110
EU - Europa 3770
AS - Asia 1062
SA - Sud America 38
AF - Africa 32
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 13
Totale 11049
Nazione #
US - Stati Uniti d'America 6063
DK - Danimarca 1388
CN - Cina 685
IT - Italia 669
DE - Germania 352
FR - Francia 319
FI - Finlandia 214
SE - Svezia 176
UA - Ucraina 175
KR - Corea 131
AT - Austria 117
GB - Regno Unito 113
PL - Polonia 103
VN - Vietnam 72
IN - India 53
CA - Canada 36
JP - Giappone 36
BE - Belgio 26
NL - Olanda 26
AU - Australia 23
ES - Italia 23
BR - Brasile 21
ID - Indonesia 16
TW - Taiwan 14
RU - Federazione Russa 13
TH - Thailandia 13
ZA - Sudafrica 13
CH - Svizzera 11
EU - Europa 11
RO - Romania 11
GR - Grecia 9
TR - Turchia 8
CO - Colombia 7
EG - Egitto 6
MX - Messico 6
SA - Arabia Saudita 6
HR - Croazia 5
IE - Irlanda 5
PK - Pakistan 5
SN - Senegal 5
CZ - Repubblica Ceca 4
HK - Hong Kong 4
PH - Filippine 4
UZ - Uzbekistan 4
AR - Argentina 3
BZ - Belize 3
CL - Cile 3
IL - Israele 3
PE - Perù 3
SG - Singapore 3
AP - ???statistics.table.value.countryCode.AP??? 2
HU - Ungheria 2
KE - Kenya 2
MY - Malesia 2
NO - Norvegia 2
RS - Serbia 2
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
HN - Honduras 1
IQ - Iraq 1
IR - Iran 1
KZ - Kazakistan 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NA - Namibia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UG - Uganda 1
Totale 11049
Città #
Ann Arbor 2688
Beijing 497
Fairfield 333
Torino 300
Houston 269
Wilmington 239
Villeurbanne 226
Dearborn 200
Woodbridge 195
Chandler 166
Princeton 143
Ashburn 135
Jacksonville 132
Medford 129
Seattle 124
Redwood City 110
Cambridge 107
Vienna 107
Warsaw 98
Fremont 60
Pisa 60
Milan 41
Boston 40
San Diego 30
Dong Ket 26
Nanjing 26
Toronto 23
Guangzhou 20
Hefei 20
Verona 20
Munich 18
Norwalk 17
Shanghai 17
Jakarta 13
Paris 13
Kunming 12
Nürnberg 12
Falls Church 11
Nyköping 11
Phoenix 11
Rome 10
Taipei 10
Brussels 9
Jinan 9
Omaha 9
Zhengzhou 9
Dallas 8
Raritan 8
Buffalo 7
Chengdu 7
Minneapolis 7
Mountain View 7
Silver Spring 7
Göteborg 6
Mumbai 6
Nanchang 6
San Mateo 6
Tokyo 6
Düsseldorf 5
Hangzhou 5
Kharkiv 5
Los Angeles 5
Louvain 5
Medellín 5
Ottawa 5
Piemonte 5
Santa Cruz 5
Xian 5
Apo 4
Bethesda 4
Brescia 4
Central District 4
Des Moines 4
Durban 4
Fuzhou 4
Henderson 4
Indianapolis 4
New York 4
Shenyang 4
Toulouse 4
Ankara 3
Bangalore 3
Barcelona 3
Belize City 3
Bucharest 3
Cape Town 3
Changsha 3
Dublin 3
Hamburg 3
Lachine 3
Lanzhou 3
Leawood 3
Leiden 3
Lima 3
London 3
Memphis 3
Modena 3
Moscow 3
Ravenna 3
Redmond 3
Totale 6994
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 353
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 301
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 297
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 278
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 254
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 254
Raltegravir penetration in seminal plasma of healthy volunteers. 227
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 224
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 223
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 213
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 213
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 204
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 197
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 182
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 178
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 158
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 155
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 144
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 141
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 141
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 141
Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes 141
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 139
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 136
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 134
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 133
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 132
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification 132
TCH-042 Stability Study of Ganciclovir in 0.9% Sodium Chloride in Different Types of Containers: Optimization of Resources 131
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 128
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 127
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 127
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 127
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 126
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 126
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 125
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 125
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 124
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 123
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 122
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 122
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 121
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 121
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 120
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 117
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 117
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 117
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 117
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 116
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 116
Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 115
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 113
Cannabis FM2: optimization and standardization of galenic preparations. 113
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 113
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 112
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 111
Sviluppo di protocolli operativi standard per l’ottimizzazione di preparazioni galeniche allestite con cannabis “FM2” 111
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 109
How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? 104
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 94
Cannabinoids concentration variability in cannabis olive oil galenic preparations 86
Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. 71
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 71
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 71
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 68
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 66
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 65
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 62
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 58
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 57
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 54
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 54
Efavirenz pharmacogenetics in a cohort of Italian patients 53
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 51
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 50
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 50
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 48
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 47
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 45
Single Nucleotide Polymorphisms of ABCB1 Gene Influence Daptomycin Pharmacokinetics in Adult Patients. [A-1769] 44
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 44
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole 44
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 42
Impact of Different Procedures of Galenic Formulations of Cannabis on Cannabinoids Contents 42
Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability 42
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 41
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 41
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 40
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 40
Class-specific relative genetic contribution for key antiretroviral drugs 40
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 39
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma 39
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 38
Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml 38
Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old 37
Pharmacogenetic determinants of imatinib, dasatinib and nilotinib pharmacokinetics in chronic myeloid leukaemia patients 36
Influence of CYP2C19 and ABCB1 genetic polymorphisms on voriconazole levels in haematological patients. [A-1937] 36
Totale 11459
Categoria #
all - tutte 14515
article - articoli 0
book - libri 0
conference - conferenze 5646
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20161

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018962 0000 037 43182 4571545435
2018/2019913 53158434 3671 48110 39100208115
2019/20203025 737159233 374569 257133 132281363480
2020/20211515 354514286 8877 7649 105123105359
2021/20223317 324298318346 249277 355285 20598287275
2022/2023394 2081114332 00 00 0000
Totale 11781